Program
sintilimab
Also written as “Sintilimab”, “IBI308” and “IBI939+ Sintilimab”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Hepatocellular · Stomach Neoplasms · Colorectal Neoplasms · Esophageal Squamous Cell Carcinoma, led by 10 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 295 open or running | phase 3since May 7, 2017 | Oct 8, 2016 | Mar 25, 2030phase 3 · NCT07917468 |
| HUTCHMED | 31 open or running | phase 3since Aug 16, 2022 | Mar 27, 2019 | Jan 8, 2029phase 3 · NCT06584032 |
| Beijing Aosaikang Pharmaceutical | 11 open or running | phase 2since Nov 21, 2022 | Nov 21, 2022 | none ahead |
| Chipscreen Biosciences | 11 open or running | phase 3since Jun 28, 2024 | Jun 28, 2024 | May 31, 2028phase 3 · NCT06497985 |
| CSPC Pharmaceutical Group | 11 open or running | phase 2since Jul 30, 2026 | Jul 30, 2026 | Sep 30, 2029phase 2 · NCT07761286 |
| Sichuan Luzhou Buchang Biopharmaceutical | 11 open or running | phase 1since Jan 2, 2025 | Jan 2, 2025 | none ahead |
| Simcere Pharmaceutical Group | 10 open or running | phase 1since Jan 29, 2023 | Jan 29, 2023 | none ahead |
| Suzhou Zelgen Biopharmaceuticals | 11 open or running | phase 2since Aug 14, 2024 | Aug 14, 2024 | none ahead |
| TaiRx | 11 open or running | phase 2since Mar 31, 2026 | Mar 31, 2026 | Dec 31, 2027phase 2 · NCT07521852 |
| TJ Biopharma | 11 open or running | phase 2since May 21, 2025 | May 21, 2025 | none ahead |
Also a collaborator on its studies: fortrea.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 26 studies since Oct 8, 2016.
- Oct 5, 2022Phase 2 study in MelanomaInnovent Biologics · NCT05572463 · United States, Australia, France and more
- Nov 21, 2022Beijing Aosaikang Pharmaceutical's first study: phase 2 study in Stomach NeoplasmsNew to Beijing Aosaikang PharmaceuticalBeijing Aosaikang Pharmaceutical · NCT05632939 · 62 enrolled · China
- Jan 29, 2023Simcere Pharmaceutical Group's first study: phase 1 study in Advanced Solid TumorsNew to Simcere Pharmaceutical GroupSimcere Pharmaceutical Group · NCT05718219 · 49 enrolled · China
- Apr 17, 2023Phase 2 study in Non-squamous Non-small-cell Lung CancerInnovent Biologics · NCT05849246 · 4 enrolled · China
- Jun 28, 2024Chipscreen Biosciences's first study: phase 3 study in Colorectal NeoplasmsNew to Chipscreen BiosciencesChipscreen Biosciences · NCT06497985 · 430 planned · China
- Aug 14, 2024Suzhou Zelgen Biopharmaceuticals's first study: phase 2 study in Carcinoma, HepatocellularNew to Suzhou Zelgen BiopharmaceuticalsSuzhou Zelgen Biopharmaceuticals · NCT06558227 · 90 planned · China
- Aug 21, 2024Phase 3 study in Endometrial NeoplasmsHUTCHMED · NCT06584032 · 412 planned · China
- Jan 2, 2025Sichuan Luzhou Buchang Biopharmaceutical's first study: phase 1 study in Stomach NeoplasmsNew to Sichuan Luzhou Buchang BiopharmaceuticalSichuan Luzhou Buchang Biopharmaceutical · NCT06773312 · 80 planned · China
- May 21, 2025TJ Biopharma's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to TJ BiopharmaTJ Biopharma · NCT07005336 · 150 enrolled · China
- Mar 16, 2026Phase 2 study in CLDN18.2 PositiveInnovent Biologics · NCT07483567 · 90 planned · China
- Mar 31, 2026TaiRx's first study: phase 2 study in Carcinoma, HepatocellularNew to TaiRxTaiRx · NCT07521852 · 40 planned · China
- Jun 4, 2026Phase 3 study in Resectable Gastric/Gastroesophageal Junction AdenocarcinomaInnovent Biologics · NCT07643623 · 720 planned · China
- Jul 30, 2026CSPC Pharmaceutical Group's first study: phase 2 study in Carcinoma, HepatocellularNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07761286 · 288 planned · China
- Oct 19, 2026Phase 3 study in Locally Advanced Rectal CancerInnovent Biologics · NCT07917468 · 500 planned · China
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularTaiRx · NCT07521852
- May 31, 2028Primary completion: phase 3 study in Colorectal NeoplasmsChipscreen Biosciences · NCT06497985
- Jan 8, 2029Primary completion: phase 3 study in Endometrial NeoplasmsHUTCHMED · NCT06584032
- Sep 30, 2029Primary completion: phase 2 study in Carcinoma, HepatocellularCSPC Pharmaceutical Group · NCT07761286
TargetBeta
“A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), ”NCIt, by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 40 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07917468Locally Advanced Rectal Cancer · China | 3 | Not yet recruiting | Innovent Biologics | Mar 25, 2030 | 500 |
| NCT07761286Carcinoma, Hepatocellular · China | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Sep 30, 2029 | 288 |
| NCT07643623Resectable Gastric/Gastroesophageal Junction Adenocarcinoma · China | 3 | Recruiting | Innovent Biologics | Dec 31, 2031 | 720 |
| NCT07521852Carcinoma, Hepatocellular · China | 2 | Recruiting | TaiRx | Dec 31, 2027 | 40 |
| NCT07483567CLDN18.2 Positive · China | 2 | Recruiting | Innovent Biologics | Jun 30, 2030 | 90 |
| NCT07005336Carcinoma, Non-Small-Cell Lung · China | 2 | Active, not recruiting | TJ Biopharma | Aug 30, 2026 | 150 |
| NCT06773312Stomach Neoplasms · China | 1 | Recruiting | Sichuan Luzhou Buchang Biopharmaceutical | Oct 2026 | 80 |
| NCT06584032Endometrial Neoplasms · China | 3 | Recruiting | HUTCHMED | Jan 8, 2029 | 412 |
| NCT06558227Carcinoma, Hepatocellular · China | 2 | Recruiting | Suzhou Zelgen Biopharmaceuticals | Sep 2026 | 90 |
| NCT06497985Colorectal Neoplasms · China | 3 | Recruiting | Chipscreen Biosciences | May 31, 2028 | 430 |
| NCT05849246Non-squamous Non-small-cell Lung Cancer · China | 2 | Terminated | Innovent Biologics | Nov 30, 2023 | 4 |
| NCT05718219Advanced Solid Tumors · China | 1 | Terminated | Simcere Pharmaceutical Group | Apr 30, 2025 | 49 |
| NCT05632939Stomach Neoplasms · China | 2 | Active, not recruiting | Beijing Aosaikang Pharmaceutical | Oct 31, 2025 | 62 |
| NCT05572463Melanoma · United States, Australia, France and more | 2 | Withdrawn | Innovent Biologics | Jun 30, 2027 | 0 |
| NCT05522231Advanced Renal Cell Carcinoma · China | 3 | Completed | HUTCHMED | Aug 28, 2026 | 265 |
| NCT05337267Healthy Male Subjects · China | 1 | Completed | Innovent Biologics | May 24, 2023 | 117 |
| NCT05280626Lymphoma, Large B-Cell, Diffuse | 2 | Not yet recruiting | Innovent Biologics | Dec 31, 2025 | 100 |
| NCT05119998Solid Tumor · China | 1 | Completed | Innovent Biologics | Jul 27, 2023 | 48 |
| NCT05116462Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Innovent Biologics | Sep 30, 2026 | 506 |
| NCT05039658DLBCL · China | 1 | UNKNOWN | Innovent Biologics | Jul 12, 2022 | 50 |
| NCT04675983Gastric Adenocarcinoma · China | 3 | Terminated | Innovent Biologics | Feb 12, 2023 | 36 |
| NCT04427774Advanced or Metastatic Solid Tumors · China | 1 | Terminated | Innovent Biologics | Feb 8, 2021 | 8 |
| NCT04401813Advanced Hepatocellular Carcinoma · China | 1 | Completed | Innovent Biologics | Jun 21, 2024 | 97 |
| NCT04353830Advanced Malignancies · China | 1 | Completed | Innovent Biologics | May 11, 2022 | 34 |
| NCT04277663Acral Melanoma That Has Been Removed by Surgery · China | 3 | Terminated | Innovent Biologics | Feb 28, 2023 | 136 |
| NCT04258111Colorectal Neoplasms · China | 2 | Terminated | Innovent Biologics | Oct 26, 2020 | 4 |
| NCT04177290Carcinoma, Non-Small-Cell Lung · China | 1 | Completed | Innovent Biologics | Feb 28, 2021 | 48 |
| NCT04085185Advanced Malignancies · China | 1 | UNKNOWN | Innovent Biologics | Dec 15, 2023 | 268 |
| NCT04044222Classic Hodgkin's Lymphoma · China | 3 | UNKNOWN | Innovent Biologics | Jul 30, 2023 | 240 |
| NCT03903705Advanced Solid Tumor · China | 2 | Completed | HUTCHMED | Nov 15, 2023 | 348 |
| NCT03802240Non-Squamous Non-Small Cell Lung Cancer · China | 3 | Completed | Innovent Biologics | Jul 31, 2021 | 492 |
| NCT03745170Stomach Neoplasms · China | 3 | Completed | Innovent Biologics | Jun 20, 2021 | 650 |
| NCT03748134Esophageal Squamous Cell Carcinoma · United States, Australia, Belgium and more | 3 | Completed | Innovent Biologics | Sep 9, 2021 | 746 |
| NCT03629925Squamous NSCLC · China | 3 | Completed | Innovent Biologics | Mar 25, 2020 | 357 |
| NCT03607539Lung Neoplasms · China | 3 | Completed | Innovent Biologics | Nov 15, 2019 | 397 |
| NCT03568539Advanced/Metastatic Solid Malignancies · United States | 1 | Completed | Innovent Biologics | Nov 9, 2020 | 39 |
| NCT03228836Effect of Drugs · China | 2 | Completed | Innovent Biologics | Feb 28, 2020 | 28 |
| NCT03150875Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Innovent Biologics | Feb 22, 2023 | 290 |
| NCT03116152Esophageal Squamous Cell Carcinoma · China | 2 | Completed | Innovent Biologics | Oct 2, 2019 | 190 |
| NCT02937116Neoplasms · China | 1 | Completed | Innovent Biologics | Sep 30, 2020 | 233 |
How it is read
Names in the registry
- “Sintilimab”, 15 entries
- “IBI308”, 5 entries
- “IBI939+ Sintilimab”, 2 entries
- “IBI110+ Sintilimab”, 2 entries
- “fruquintinib+sintilimab”, 1 entry
Codes read as this program: IBI308.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 6 studies
- Carcinoma, Hepatocellular, 4 studies
- Stomach Neoplasms, 3 studies
- Colorectal Neoplasms, 2 studies
- Esophageal Squamous Cell Carcinoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.